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Abstract 
A study with the objective of determining the rate of individual compliance to annual ivermectin treatment was 
conducted in Abia State, south eastern Nigeria between January and November, 2011. The study captured the 
Local Government Areas in  Abia State that were assessed by Rapid  Epidemiological Mapping for 
Onchocerciasis (REMO) as being hyper-endemic for onchocerciasis and which have been receiving ivermectin 
for over 14 years. A study questionnaire was designed to investigate the rate of compliance and this was 
distributed to 558 individuals. The result showed that out of 558 individuals, 309 (55.4%) had taken the drug 
before while 249 (44.6%) claimed they have not been treated before. Despite the treatment over time, only 70 
(22.7%) of those treated before were high compliers (that is, those who had been treated eight times and above). 
The overall percentage of high compliers in the sampled communities was only 12.6%. Reasons for low 
compliance include “lack of information on the arrival of drug” (27.8%), “no reason for refusal” (22.2%),” 
absent, away from village” (20.0%) and “no distribution” (19.7%). In testing the reasons for low compliance, the 
Chi-square analytical technique on the data revealed that the reasons given by the respondents for low 
compliance were not significant (χ2cal = 1.797 < χ2tab = 16.9190), and therefore do not affect general compliance.  
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1. Introduction 
Onchocerciasis is one of the most important chronic parasitic diseases afflicting millions of people in the tropical 
and sub-tropical zones. It is one of the major endemic diseases which in addition to causing untold human 
suffering, is a major obstacle to socioeconomic development (WHO, 1995). Onchocerciasis is prevalent in about 
37 countries of the world and is the world’s second leading cause of blindness (Nwoke et al., 2006) Thirty of 
these endemic countries are in tropical Africa, south of the Sahara; six are in Central and South America and one 
in Yemen, the Arabian Peninsula (Haslett et al., 2002). Clinically, Onchocerciasis is associated with a lot of 
ocular and dermal manifestations.  More than 123 million people live in endemic areas, and an estimated 17.7 
million people are currently infected (WHO, 1995; Global 2000 RBP, 1998; http: //www.cdc.gov., 2008). It is the 
blinding implication of the disease that has made it one of the major targets for control by World Health 
Organization (WHO, 1995).  
Currently, ivermectin (Mectizan), a semi-synthetic macrocyclic lactone produced by the actinomycete, 
Streptomyces avermitilis sp,  developed by Merck & Co. Inc. and launched commercially in 1981, was shown to 
be an effective drug for the treatment of  onchocerciasis. Ivermectin is a very effective microfilaricide that kills 
99% of microfilariae with a single treatment (APOC/ WHO, 2005). With the mandate of APOC to establish  
within a period of 12 to 15 years, effective and self-sustainable community- directed treatment with ivermectin 
throughout  the endemic areas, within the geographical scope of the programme (APOC/WHO, 2005), it requires 
a clear understanding of the long-term compliance process in order to guide countries towards sustainability. 
According to projections by epidemiologists, it is believed that onchocerciasis could be controlled in endemic 
communities if 100% of eligible populations take their treatment regularly over a period of 10 to 15 years or 
more (Edungbola, 1991; Boussinesq et al., 1997).  With annual dose of ivermectin, it is estimated that 70% of 
target population would have to be treated, for the long-term project of elimination of the disease to be a reality 
(Dadzie, 1997).  Compliance with annual ivermectin treatment therefore, has become a major challenge for 
APOC as it enters its second decade of implementation. Now that the original 25 projects which started in 1997 
– 1998 have been operating for more than a decade, annual compliance studies have become possible. Such 
studies are extremely desirable since researchers are now pushing back the timeframe for annual ivermectin 
dosing from 15 to 25 or more years (Winnen et al., 2002) and coverage rate from 65% to 80% (APOC/WHO, 
2009).   
To date, published reports of CDTI intervention have focused on coverage. While reports of population coverage 
are encouraging (Amazigo et al., 2007), only few studies have centered on compliance to annual ivermectin 
treatment. Coverage rates in a community may not give the full picture of the programme success because there 
may be individuals or groups who systematically do not comply over the years and thus provide a continued 
focus for the disease transmission. Few unpublished reports have shown that in a good number of communities, 
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women are excluded from annual ivermectin treatment for various reasons (Elhassan et al., 2007). Studies 
showing gender differences in coverage imply longer term problems with compliance (Brieger et al, 2002; 
Maduka et al., 2004). However, this question needs to be tested through properly designed research. The present 
study is designed to determine the rate of compliance to annual ivermectin treatment which has lasted for over 
14 years in Abia State.  
 
2. Materials and Methods 
2.1. Study Area: The study was carried out in Abia State located in the rainforest zone of South eastern Nigeria 
and inhabited majorly by the Ibo ethnic group. The state is made up of 17 Local Government Areas (LGAS) with 
a population of 2,883,399 people according to 2006 census. Eight (8) of the seventeen LGAs in the State are 
endemic for onchocerciasis -2 hyper-endemic and 6 meso-endemic (Ukairo, 2008). The studied LGAs were 
selected based on hyper-endemicity with onchocerciasis. 
Ivermectin distribution commenced in Abia State in 1995 as a combined effort of the State Ministry of Health, 
the Lions Club and the River Blindness Foundation. In 1996, the Carter Center’s Global 2000 Programme 
assumed the River Blindness Foundation partner role. In 1998, Abia State began receiving APOC support and 
currently, the programme has lasted over 14 years. 
2.2. Preliminary Survey and Advocacy: The pre-disease survey logistics included visits to the Local 
Government Chairman of the two LGAs (Umunneochi and Isuikwuato LGAs), the traditional rulers of the 
autonomous communities (4 communities from each LGA) and the village heads to explain the purpose of the 
survey and to solicit for co-operation. 
 
2.3. Data Collection and Analysis: The study questionnaire designed to investigate the rate of compliance and 
reasons for absenteeism was administered to 558 individuals. A specially designed individual form was used to 
elicit information on the respondent’s personal data. To elucidate the issue of recall bias in this study (since most 
people do not remember things easily beyond five years), treatment registers were used to compare the claims of 
respondents on number of times the drug was swallowed. Where treatment registers were not available or 
inadequate, the claims of the individuals were weighed with the report of CDDs.  
 
2.4. Statistical Analysis 
 A well designed questionnaire was used to evaluate the rate of compliance to annual ivermectin treatment. The 
data obtained was expressed in percentages. This result was also expressed in a Bar chart for a quick 
appreciation of the data. Chi-square (X2) technique was used to determine the level of significance of the 
demographic factors on compliance and the reasons for low compliance. 
 
3. Results 
Of the 558 individuals interviewed to ascertain their level of compliance, 306 (55.4%) had taken the drug before 
while 249 (44.6%) claimed they had not been treated before (Table 1). This result was also expressed in a Bar 
chart for a quick appreciation of the data (Figure 1). Despite the treatment over time, only 70 (22.7%) of those 
treated before were high compliers, that is, those who had been treated for 8 times and above. Two hundred and 
thirty nine (77.3%) of those treated before were low compliers. The overall percentage of high compliers in the 
sampled communities was only 12.6%. The result also revealed the age range of the individuals who claimed 
they had not taken the drug before (Table 2).  Out of 249 individuals who had not taken the drug before, 90 
(36.1%) are between the age bracket of 6-11 years; 51 (20.1%) fall between the age bracket of 12-24 years while 
108 (43.4%) are 25 ye years and above. 
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Table 1: The Rate of Compliance to Ivermectin Treatment in the Sampled Communities 
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% 
freq. 
 
 
 
 
 
 
 
 
     12.6% 
      High     
compliers 
 
0 23 17 22 56 24 13 24 70 249 44.6 
1 08 09 05 09 17 10 07 02 67 12.0 
2 12 10 04 06 15 06 07 01 61 10.9 
3 07 07 02 10 09 03 11 - 49 8.8 
4 03 04 - 01 10 06 02 - 26 4.7 
5 02 03 - 04 03 - 05 01 18 3.2 
6 02 - 01 03 02 01 01 - 10 1.8 
7 01 01 - 01 01 - 04 - 08 1.4 
8 01 02 - 03 - - 03 - 09 1.6 
9 - 01 - 01 - - - - 02 0.4 
10 01 - 01 06 02 - 01 - 11 2.0 
11 - - - - - - - - - - 
12 01 01 - - 02 - - - 04 0.7 
13 04 - - - 02 - - 04 07 1.3 
≥14 - 08 01 - 19 03 06 - 37 6.3 
Total 65 63 36 100 106 42 71 75 558 100 
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Figure 1: Compliance Rate Expressed in Bar Chart 
 
Table 2: Age Range of Individuals who claimed they have not taken the Drug before 
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6 – 11 6 13 3 26 6 6 9 21 90 36.1 
12 – 24 7 3 10 7 5 3 7 9 51 20.5 
25 and above 10 1 9 23 13 4 8 40 108 43.4 
Total 23 17 22 56 24 13 24 70 249 44.6 
           
 
 
 
The frequency of high compliers in the sampled communities shows that Mbala- Isuochi has a high compliance 
rate of 23.6%, Amiyi-Obilohia (19.0%), Umuobiala (10.8%), and Amiyiuhu (10.0%), while the least was 
Lokpanta with compliance rate of 1.3% (Table 3). 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.3, No.12, 2013 
 
20 
Table 3: Frequency of High Compliers in the Sampled Communities  
Community No sampled Freq. of high compliers (8 to ≥ 14) Percentage (%) 
Umuobiala 
Amiyi-obilohia 
Obiagu-Uturu 
Amiyiuhu 
Mbala-Isuochi 
Amuda-Isuochi 
Amakpoke 
Lokpanta 
65 
63 
36 
100 
106 
42 
71 
75 
07 
12 
02 
10 
25 
3 
10 
1 
10.8 
19.0 
2.8 
10.0 
23.6 
7.1 
14.1 
1.3 
 
 
 
 
 
 
 
The effect of demographic factors on compliance (Table 4), revealed that 195 (34.9%) out of 558 individuals 
interviewed were males while 363 (65.1%) were females. Among these groups, 53.8% and 57.3% of the males 
and females respectively were treated before. Out of the 195 males and 363 females, only 25 (12.8%) males and 
45 (12.4%) females were high complier. However, the Chi-square (X2) analysis at 0.05 level of significance 
revealed that sex does not affect the rate of compliance to drug (i.e. χ2cal. =2.41 < χ2tab. =11.34). Stratifying by 
age, the result revealed that out of 558 individuals interviewed, 89 (15.9%) were between ages 6-11; 67 (12.0%) 
were between 12-24 years, while 402 (72.0%) were 25 years and above. Among the ages of 25 years and above, 
289 (71.9%) had been treated before with 69 (17.2%) as high compliers. Among ages 12-24, only 8 (11.9%) had 
been treated before with 1(1.5%) as high complier. Among the 89 individuals between 6-11 years interviewed, 
only 18 (20.2%) had been treated before. The statistical analysis revealed that age has a great effect on the intake 
of drug and compliance (i.e. χ2cal. = 68.145 > χ2tab. =16.8119). On education and levels of education, the result 
showed that education and levels of education do not contribute to any significant difference in the drug 
consumption within the demographic location under statistical investigation (i.e. χ2cal=7.14 < χ2tab =16.8119). 
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Table 4: Effects of Demographic Factors on Compliance 
 
Factors 
Sample 
number 
N=558 
No. treated 
before and 
percentage (%) 
No. of  high 
compliers % compliance 
Yates 
χ
2
  
value, P 
 
Sex 
 
Male 
Female 
 
195 
363 
 
105 (53.8) 
208 (57.3) 
 
25 
45 
 
12.8 
12.4 
 
2.41< χ2tab  
Age 6-11yrs 
12-24yrs 
25 and above  
89 
67 
402 
18 (20.2) 
08 (11.9) 
289 (71.9) 
Nil 
01 
69 
 
1.5 
17.2 
68.145> χ2tab 
Education  None 
Primary 
Secondary 
174 
242 
142 
125 (71.8) 
119 (49.6) 
67 (47.2) 
23 
25 
14 
13.2 
10.3 
9.9 
7.14 < χ2tab   
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Table 5: Reasons for low compliance among community members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore χ2cal = 1.797 
Whereχ2tab = 16.9190 
 
4.  Discussion 
Onchocerciasis control can be achieved through several years of high treatment coverage and compliance. 
However, compliance to annual ivermectin treatment has become a challenge as low compliance implies longer 
time of elimination and thus more cost effective. The result from this survey revealed that 44.6% of the 
communities sampled had not been treated before and only 12.6% were high compliers. Mbala-Isuochi that 
started treatment in 1991 has high compliance rate of 23.6% followed by Amiyi Obilohia (where microfilariae 
were identified) with 19.0% while the least was Lokpanta with compliance rate of 1.3%. The non-compliance 
and low-compliance groups may serve as a reservoir for continued transmission of onchocerciasis. Results from 
the demographic survey on households revealed that gender and level of education did not affect compliance. 
This could be as a result of health enlightenment and the benefits received or seen on those treated with 
ivermectin.  This agrees with the report on compliance to annual ivermectin treatment by Elhassan et al (2007) in 
Kaduna State where gender and level of education did not affect compliance. However, age had a significant 
effect on compliance as the adults were mostly available for treatment while the youths were away in cities 
schooling or working. This is supported by an FGD participant who said that the elderly are more in the village 
while the youths travel outside for work. The level of compliance is also affected by side reactions following 
drug treatment. These side reactions include swelling of the body, discomfort, dizziness, fever, itching and 
sleepiness. 
The major reasons for low compliance by respondents include “lack of information on the arrival of the drug”, 
“no reason for refusal” and “absenteeism”. Refusal to comply with annual ivermectin treatment could be 
attributed to lack of adequate information on the benefits of the drug and the fear for side reactions. A 
respondent stated clearly that his reason for refusal was the side effects he saw on others who took the drug. 
Absent, away from village was also identified as an important factor detrimental to compliance. Absent, away 
from village may be due to farming, where community members went to their farms very early and back very 
late and therefore could not be seen at home for treatment; or where people travel outside the village for work 
and other opportunities and miss annual distribution. Emukah et al (2004) also identified “absent, away from 
village’’ as a major factor that contributed to low compliance to annual ivermectin treatment. It is therefore 
recommended that awareness should be created through health enlightenment campaign on the importance of 
compliance to annual ivermectin treatment. The treatment could be biannual to accommodate those absent from 
community during the previous treatment period. It is believed that the implementation of these suggestions will 
No Reasons 
io  
frequency 
% 
ie  
i
ii
e
eo 2)( −
 
01 Seriously sick at home 09 1.6 8.928 0.00058 
02 Pregnant at home 09 1.6 8.928 0.00058 
03 Under age 5 at time 34 6.1 34.038 0.0000424 
04 To short at time 01 0.2 1.116 0.012 
05 Absent, away from village 111 20.0 111.6 0.0032 
06 Side effect of ivermectin  18 3.2 17.856 0.00116 
07 Don’t take orthodox drug = = = = 
08 Not informed 155 27.8 155.124 0.000099 
09 Refused/ no reason 124 22.2 123.318 0.00377 
10 Drug had finished 01 0.2 1.116 0.012 
11 No distribution 96 19.7 109.926 1.764 
 
Total 558   1.797 
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not only improve compliance to annual ivermectin treatment but also boost the long-term compliance that will 
eventually eradicate onchocerciasis in Abia State, Nigeria.  
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